Mat Legut, OverT Bio CEO
Exclusive: New York biotech debuts with $16M to find new ways to make solid cancer cell therapies
A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had limited …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
